MetaBlok™

Potential Treatment to Prevent Organ Inflammation

Metablok (LSALT peptide) is our lead drug candidate for treating inflammation in the lungs, liver and kidneys.. 

Arch believes Metablok has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role. In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal Cell  describing a novel mechanism of action for organ inflammation. In the publication, the enzyme...

FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients

  • International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in patients infected with COVID-19 
  • Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents...

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver

Authors

Saurav Roy Choudhury, Liane Babes, Jennifer J. Rahn, Bo-Young Ahn, Kimberly-Ann R. Goring, Jennifer C. King, Arthur Lau, Björn Petri, Xiaoguang Hao, Andrew K. Chojnacki, Ajitha Thanabalasuriar, Erin F. McAvoy, Sébastien Tabariès, Christoph...

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is currently a Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular Biology. He is a former Canada Research Chair...

    Bridging the gap between science and business

    Bringing new medical innovation to market.

    Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual...

    News &
    Publications

    Arch Biopartners Closes Non-Brokered Private Placement

    TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates...

    Arch Biopartners Arranges Non-Brokered Private Placement

    TORONTO, June 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates...

    Stock information

    Arch Biopartners trades as ARCH:TSXV in Canada, and ACHFF:OTCBB in the United States.

    Management and Board of Directors

    Investor Relations and Investor Information